太龍藥業(600222.SH)擬1.279億元收購太龍健康33.95%股權
格隆匯11月30日丨太龍藥業(600222.SH)公佈,公司擬以現金支付的方式,收購控股股東眾生集團持有的太龍健康產業投資有限公司(以下簡稱“太龍健康”)33.95%的股權,收購價格人民幣1.279億元。本次交易完成後,公司將持有太龍健康80.40%的股權,能夠對其實施控制,將其納入公司合併報表範圍。
太龍健康主要投資於醫藥健康領域的產業基金,鑑於前期所投資的項目發展趨勢已基本明朗,投資回報趨於明確,未來經營業績可期;同時未來可進一步發揮其投資平台的作用,協助公司發掘醫藥健康領域的投資機會,增加與公司產業發展的協同效應。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.